Background and aim: Peutz-Jeghers syndrome (PJS) and juvenile polyposis syndrome (JPS) are autosomal dominant diseases associated with high cancer risk. In Japan, knowledge about the prevalence and incidence of PJS and JPS is lacking despite being crucial for providing appropriate medical support. We aimed to determine the prevalence and incidence of these diseases.
Methods: In 2022, a nationwide questionnaire survey was conducted to determine the number of patients with PJS or JPS by sex and the number of newly confirmed cases from 2019 to 2021. The target facilities included gastroenterology, pediatrics, and pediatric surgery departments, which were stratified into seven classes on the basis of the total number of beds. We randomly selected target facilities using different extraction rates in each class, resulting in 1748/2912 facilities (extraction rate: 60%) as the final sample. We calculated the estimated number of patients using the response and extraction rates.
Results: A total of 1077 facilities responded to the survey. The estimated numbers of patients with PJS and JPS were 701 (95% confidence interval [CI]: 581-820) and 188 (95% CI: 147-230), respectively. The 3-year period prevalences of PJS and JPS were 0.6/100000 and 0.15/100000, whereas the incidences in 2021 were 0.07/100000 and 0.02/100000, respectively. Male patients constituted 53.5% and 59.6% in the PJS and JPS groups, respectively.
Conclusions: We determined the prevalence and incidence of PJS and JPS in Japan for the first time. Further research is needed to obtain more detailed information, including the clinical differences and outcomes in Japan.
{"title":"Prevalence and Incidence of Peutz-Jeghers Syndrome and Juvenile Polyposis Syndrome in Japan: A Nationwide Epidemiological Survey in 2022.","authors":"Yuri Matsubara, Yosikazu Nakamura, Yoshiko Nakayama, Tomonori Yano, Hideki Ishikawa, Hideki Kumagai, Junji Umeno, Keiichi Uchida, Keisuke Jimbo, Toshiki Yamamoto, Hideyuki Ishida, Okihide Suzuki, Koichi Okamoto, Fumihiko Kakuta, Yuhki Koike, Yuko Kawasaki, Hirotsugu Sakamoto","doi":"10.1111/jgh.16839","DOIUrl":"https://doi.org/10.1111/jgh.16839","url":null,"abstract":"<p><strong>Background and aim: </strong>Peutz-Jeghers syndrome (PJS) and juvenile polyposis syndrome (JPS) are autosomal dominant diseases associated with high cancer risk. In Japan, knowledge about the prevalence and incidence of PJS and JPS is lacking despite being crucial for providing appropriate medical support. We aimed to determine the prevalence and incidence of these diseases.</p><p><strong>Methods: </strong>In 2022, a nationwide questionnaire survey was conducted to determine the number of patients with PJS or JPS by sex and the number of newly confirmed cases from 2019 to 2021. The target facilities included gastroenterology, pediatrics, and pediatric surgery departments, which were stratified into seven classes on the basis of the total number of beds. We randomly selected target facilities using different extraction rates in each class, resulting in 1748/2912 facilities (extraction rate: 60%) as the final sample. We calculated the estimated number of patients using the response and extraction rates.</p><p><strong>Results: </strong>A total of 1077 facilities responded to the survey. The estimated numbers of patients with PJS and JPS were 701 (95% confidence interval [CI]: 581-820) and 188 (95% CI: 147-230), respectively. The 3-year period prevalences of PJS and JPS were 0.6/100000 and 0.15/100000, whereas the incidences in 2021 were 0.07/100000 and 0.02/100000, respectively. Male patients constituted 53.5% and 59.6% in the PJS and JPS groups, respectively.</p><p><strong>Conclusions: </strong>We determined the prevalence and incidence of PJS and JPS in Japan for the first time. Further research is needed to obtain more detailed information, including the clinical differences and outcomes in Japan.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ho-Su Lee, Yoonho Lee, Jiwon Baek, Yongjae Kim, Sojung Park, Seulgi Jung, Jong Geol Lee, In-Jeoung Baek, Kyuwon Kim, Sung Wook Hwang, Jong Lyul Lee, Sang Hyoung Park, Suk-Kyun Yang, Buhm Han, Kyuyoung Song, Yong Sik Yoon, Byong Duk Ye
Background and aim: We aimed to assess the gene expression profiles of nonlesional small bowels in patients with Crohn's disease (CD) to identify its accompanying molecular alterations.
Methods: We performed RNA sequencing of the uninflamed small bowel tissues obtained from 70 patients with ileal CD and 9 patients with colon cancer (non-CD controls) during bowel resection. Differentially expressed gene (DEG) analyses were performed using DESeq2. Gene set enrichment, correlation, and cell deconvolution analyses were applied to identify modules and functionally enriched transcriptional signatures of CD.
Results: A comparison of CD patients and non-CD controls revealed that of the 372 DEGs, 49 protein-coding genes and 5 long non-coding RNAs overlapped with the inflammatory bowel disease susceptibility loci. The pathways related to immune and inflammatory reactions were upregulated in CD, while metabolic pathways were downregulated in CD. Compared with non-CD controls, CD patients had significantly higher proportions of immune cells, including plasma cells (P = 1.15 × 10-4), and a lower proportion of epithelial cells (P = 1.12 × 10-4). Co-upregulated genes (M14 module) and co-downregulated genes (M9 module) were identified in CD patients. The M14 module was enriched in immune-related genes and significantly associated with the responses to anti-tumor necrosis factor (TNF) therapy. The core signature of the M14 module was comprised of six genes and was upregulated in nonresponders to anti-TNF therapy of five independent cohorts (n = 163), indicating acceptable discrimination ability (area under the receiver operating characteristic curve of 75-86%).
Conclusions: The differences in gene expression and cellular composition between CD patients and non-CD controls imply significant molecular alterations, which are associated with the response to anti-TNF treatment.
背景和目的:我们旨在评估克罗恩病(CD)患者非发炎小肠的基因表达谱,以确定其伴随的分子改变:我们对从 70 名回肠 CD 患者和 9 名结肠癌患者(非 CD 对照组)肠切除术中获得的未发炎小肠组织进行了 RNA 测序。使用 DESeq2 对差异表达基因(DEG)进行了分析。应用基因组富集、相关性和细胞去卷积分析确定了CD的模块和功能富集转录特征:结果:对 CD 患者和非 CD 对照组进行比较后发现,在 372 个 DEGs 中,49 个蛋白编码基因和 5 个长非编码 RNA 与炎症性肠病易感基因位点重叠。与免疫和炎症反应相关的通路在 CD 中上调,而代谢通路在 CD 中下调。与非 CD 对照组相比,CD 患者的免疫细胞(包括浆细胞)比例明显较高(P = 1.15 × 10-4),而上皮细胞比例较低(P = 1.12 × 10-4)。在 CD 患者中发现了共上调基因(M14 模块)和共下调基因(M9 模块)。M14模块富含免疫相关基因,与抗肿瘤坏死因子(TNF)治疗反应显著相关。M14模块的核心特征由6个基因组成,在5个独立队列(n = 163)的抗肿瘤坏死因子治疗无应答者中上调,显示了可接受的鉴别能力(接收者操作特征曲线下面积为75-86%):结论:CD患者和非CD对照组之间在基因表达和细胞组成方面的差异意味着存在重大的分子改变,这与抗肿瘤坏死因子治疗的反应有关。
{"title":"Nonlesional ileal transcriptome in Crohn's disease reveals alterations in immune response and metabolic pathway.","authors":"Ho-Su Lee, Yoonho Lee, Jiwon Baek, Yongjae Kim, Sojung Park, Seulgi Jung, Jong Geol Lee, In-Jeoung Baek, Kyuwon Kim, Sung Wook Hwang, Jong Lyul Lee, Sang Hyoung Park, Suk-Kyun Yang, Buhm Han, Kyuyoung Song, Yong Sik Yoon, Byong Duk Ye","doi":"10.1111/jgh.16816","DOIUrl":"https://doi.org/10.1111/jgh.16816","url":null,"abstract":"<p><strong>Background and aim: </strong>We aimed to assess the gene expression profiles of nonlesional small bowels in patients with Crohn's disease (CD) to identify its accompanying molecular alterations.</p><p><strong>Methods: </strong>We performed RNA sequencing of the uninflamed small bowel tissues obtained from 70 patients with ileal CD and 9 patients with colon cancer (non-CD controls) during bowel resection. Differentially expressed gene (DEG) analyses were performed using DESeq2. Gene set enrichment, correlation, and cell deconvolution analyses were applied to identify modules and functionally enriched transcriptional signatures of CD.</p><p><strong>Results: </strong>A comparison of CD patients and non-CD controls revealed that of the 372 DEGs, 49 protein-coding genes and 5 long non-coding RNAs overlapped with the inflammatory bowel disease susceptibility loci. The pathways related to immune and inflammatory reactions were upregulated in CD, while metabolic pathways were downregulated in CD. Compared with non-CD controls, CD patients had significantly higher proportions of immune cells, including plasma cells (P = 1.15 × 10<sup>-4</sup>), and a lower proportion of epithelial cells (P = 1.12 × 10<sup>-4</sup>). Co-upregulated genes (M14 module) and co-downregulated genes (M9 module) were identified in CD patients. The M14 module was enriched in immune-related genes and significantly associated with the responses to anti-tumor necrosis factor (TNF) therapy. The core signature of the M14 module was comprised of six genes and was upregulated in nonresponders to anti-TNF therapy of five independent cohorts (n = 163), indicating acceptable discrimination ability (area under the receiver operating characteristic curve of 75-86%).</p><p><strong>Conclusions: </strong>The differences in gene expression and cellular composition between CD patients and non-CD controls imply significant molecular alterations, which are associated with the response to anti-TNF treatment.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}